Your signal. Your price.
Elena Berger argues that Silicon Valley falsely claims credit for exporting wellness trends like peptides. In reality, peptide usage began in gray markets and bodybuilding subcultures in the American Midwest before being professionalized by coastal longevity clinics.
Ruby Justice Thelot details the concept of body futurism, where human optimization replaces silicon innovation. In an era of automated abundance, biological enhancement and internal metric tracking become the primary frontiers for human engineering.
Andrew Huberman refutes the claim that cold plunges chronically elevate stress hormones. Spiking cortisol intentionally in the morning through bright light, caffeine, and cold exposure actually lowers baseline cortisol levels at night, leading to better sleep.
Andrew Huberman recommends spiking cortisol in the morning with bright light and lowering it at night to optimize sleep and focus. Failing to spike morning cortisol leads to a flat cortisol curve, causing brain fog and stress.
Chris Williamson utilizes resonant biofeedback devices to raise heart rate variability. Practicing personalized resonant breathing for over 12 minutes daily shifts the nervous system from a temporary state change to a lasting trait change.
Non-sleep deep rest utilizes exhale-emphasized breathing and sensory focus to shift the brain from active planning to pure sensation. Andrew Huberman notes this practice lowers cortisol, recovers lost sleep, and accelerates neural pathways for learning.
Davidson advocates for primordial cardiovascular prevention, proposing the "8-gram rule" where 8 grams of lifetime LDL exposure triggers heart disease. Keeping lifetime LDL below 80 mg/dL can successfully prevent atherosclerosis before plaque starts to form.
Attia compares managing high LDL to smoking cessation, arguing that doctors should treat causal risk factors regardless of a young patient's low 10-year risk score. Waiting to treat a causal driver of disease defies basic preventative medicine logic.
Pfizer's early CETP inhibitor torcetrapib failed due to an off-target molecule design that stimulated aldosterone secretion in the adrenal glands. This toxic effect raised blood pressure and increased mortality, leading to the trial's termination in 2006.
Davidson notes that Roche's dalcetrapib raised HDL without changing LDL or clinical outcomes. Lilly's evacetrapib lowered LDL but was stopped for futility after only two years, which Davidson argues was too brief to show a clinical benefit.
The REVEAL trial proved that CETP inhibition lowers cardiovascular events by tracking 30,000 patients over four years. Anacetrapib lowered LDL by 17% and reduced major events by 9%, but Merck abandoned it because the lipophilic drug accumulated persistently in fat.
Obicetrapib is a highly potent CETP inhibitor that lowers LDL by up to 45% as a monotherapy. The ongoing global Prevail trial will assess cardiovascular outcomes in 9,500 patients on maximum-tolerated statins over a minimum follow-up of 2.5 years.
Obicetrapib reduces small LDL particles by 90% and lowers Lp(a) by approximately 50%. Davidson emphasizes that unlike statins, which can slightly increase diabetes risk, CETP inhibitors systematically lower the risk of developing diabetes.
The brain contains 25% of the body's cholesterol, utilizing isolated metabolism where ApoB is entirely absent. Genomic studies like the Bronx Aging Study show that CETP loss-of-function mutations eliminate the elevated Alzheimer's risk typically observed in APOE4 carriers.
In the Broadway trial, homozygous APOE4 carriers treated with obicetrapib saw over 20% reduction in the Alzheimer's biomarker p-tau 217 compared to placebo. The drug also improved other key neurodegenerative markers, including NfL and GFAP.
Davidson recounts developing Epinova, an omega-3 formulation containing EPA and DHA, which failed to show cardiovascular efficacy in the Strength Trial when tested at a 4-gram daily dose.
Chris Williamson notes that Navy SEAL selection has a strict age cutoff around 31. Jocko Willink explains that older bodies struggle to recover from extreme training incidents, such as falling from a 50-foot cargo net onto sand.
The search for the oldest active podcast host reveals Dominic Chianese, who is 95 years old and 26 days older than fellow 95-year-old host William Shatner.
Brian Armstrong co-founded New Limit to pursue epigenetic reprogramming, using machine learning to identify transcription factors that can restore youthful cell function without changing cell identity.
Brian Armstrong announces that New Limit has successfully reprogrammed a human cell type in animal models, with Phase 1 clinical trials for alcoholic liver disease launching next year.
Brian Armstrong estimates that New Limit's initial liver disease drug alone could address a $20 billion market, though the ultimate goal is systemic rejuvenation of healthy individuals.
Mammals undergo massive epigenetic reprogramming where roughly 90 percent of chemical modifications on DNA are wiped clean in early embryos. Oded Rechavi explains this erasure returns the genome to a blank slate, preserving typical species development.
Ben Greenfield cycles insulin growth factor LR3 instead of growth hormone to bypass downstream side effects like elevated cortisol and glucose. This peptide delivers the healing benefits of growth hormone without suppressing natural production.
Dr. Gabrielle Lyon microdoses GLP-1 at 0.25 mg to target systemic inflammation and potentially reduce cancer risk. She notes that the therapy also suppresses disruptive food noise during travel days.
Dr. Gabrielle Lyon warns that widespread GLP-1 usage threatens to trade obesity for sarcopenia. Because rapid weight loss often strips lean muscle mass, maintaining muscle and bone density remains critical for healthspan.
Brigham Buhler uses the Biocharger, a device that applies electromagnetic fields and radio frequencies through noble gases. Chris Williamson trialed the device for a month but noticed no physiological differences.
Chris Williamson finds that a 90 minute hard shell hyperbaric oxygen therapy session at 2.2 atmospheres provides superior cognitive clarity and energy compared to cold plunges or caffeine.
Ben Greenfield uses hydrogen inhalation because hydrogen acts as a selective antioxidant. Unlike high dose vitamin C, it quells post exercise inflammation without blunting the body's natural anabolic adaptation.
Ben Greenfield states that securing cellular heat shock protein benefits requires sitting in a 200 degree Fahrenheit sauna for 30 minutes. Users must wear wool hats at these temperatures to protect the brain from cognitive decline.
Jay Wiles developed the OMDA Health lamp to guide users toward five and a half second breathing cycles. This specific resonance rate maximizes vagal tone and optimizes heart rate variability.